Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

This study has been completed.

Study NCT00560313 Information provided by Novartis

First Received: November 16, 2007 Last Updated: November 16, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Study Completion Date:	November 2009
Estimated Primary Completion Date:	No date given